LAG3 and breast carcinoma: Several studies have addressed the beneficial usage of anti-LAG3 therapy in different malignancies: one monoclonal anti-LAG3 antibody, IMP321, was able to activate antigen-presenting cells (APCs) and T cells in breast cancer [26].